Navco Pharmaceuticals (TSXV:NAV) EV-to-EBIT : -37.36 (As of May. 11, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Navco Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Navco Pharmaceuticals's Enterprise Value is C$1.98 Mil. Navco Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was C$-0.05 Mil. Therefore, Navco Pharmaceuticals's EV-to-EBIT for today is -37.36.

The historical rank and industry rank for Navco Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

TSXV:NAV' s EV-to-EBIT Range Over the Past 10 Years
Min: -42.41 Med: 0 Max: 0
Current: -25.47

TSXV:NAV's EV-to-EBIT is not ranked
in the Drug Manufacturers industry.
Industry Median: 17.95 vs TSXV:NAV: -25.47

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Navco Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2023 was C$0.46 Mil. Navco Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was C$-0.05 Mil. Navco Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -11.52%.

Navco Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Navco Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navco Pharmaceuticals EV-to-EBIT Chart

Navco Pharmaceuticals Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

EV-to-EBIT

-3.03

-5.27

-5.60

Navco Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
EV-to-EBIT	Get a 7-Day Free Trial														-5.39	-4.53	-4.92	-6.67	-8.68

Competitive Comparison of Navco Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Navco Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Navco Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Navco Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Navco Pharmaceuticals's EV-to-EBIT falls into.

Navco Pharmaceuticals EV-to-EBIT Calculation

Navco Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1.980	/	-0.053
	=	-37.36

Navco Pharmaceuticals's current Enterprise Value is C$1.98 Mil.
Navco Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.05 Mil.

Navco Pharmaceuticals (TSXV:NAV) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Navco Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2023 )	=	EBIT	/	Enterprise Value (Q: Mar. 2023 )
	=	-0.053	/	0.46
	=	-11.52 %

Navco Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2023 was C$0.46 Mil.
Navco Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.05 Mil.

Navco Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Navco Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Navco Pharmaceuticals (TSXV:NAV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Navco Pharmaceuticals Inc (TSXV:NAV) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 West Georgia Street, Suite 1500, Vancouver, BC, CAN, V6E 4N7

Website

Navco Pharmaceuticals Inc uses of nanotechnology to develop and commercialize novel products to protect against viruses, bacteria, and infectious diseases. The company's pipeline of applications is tailored to defend against pathogens utilizing new methods of action to capitalize on unmet product needs using natural & known compounds, nanoparticles, and no chemicals with a high degree of efficacy. Its target markets include human health & personal skin care, household & institutional products, and veterinary health.